Beam Therapeutics Reports Third Quarter 2026 Financial Results and Highlights
Exhibit 99.1 Beam Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Clinical Progress Across Base Editing Portfolio
Updated BEAM-302 Phase 1/2 Clinical Data Presented at ERS Demonstrated Durable Increases in Functional AAT and Reductions in Mutant Z-AAT; Completion of Dosing in the Global Pivotal Cohort Expected in First Half of 2027
U.S. Biologics License Application (BLA) Submission for Risto-cel in Sickle Cell Disease Expected as Early as Year-End 2026
Dosing in Phase 1/2 Trial of BEAM-304 in PKU Anticipated to Initiate in Early 2027
Initial BEAM-301 Phase 1/2 Data Presented at ESGCT Demonstrated Clinical Proof of Concept for Genetic Correction of R83C Mutation in GSDIa; Enrollment in 60 mg Cohort Underway
Ended Third Quarter 2026 with $1.0 Billion in Cash, Cash Equivalents and Marketable Securities; Cash Runway Expected to Support Operating Plans into Mid-2029 Cambridge, Mass., November 3, 2026– Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported third quarter 2026 financial results and provided updates across the company’s hematology and genetic disease franchises.
“Our progress this quarter reflects the growing maturity and momentum of Beam’s platform, with predictable clinical translation across four distinct programs and multiple potentially transformative medicines advancing toward patients, bringing our vision for a new era of genetic medicine increasingly within reach,” said John Evans, chief executive officer of Beam Therapeutics. “We are approaching a potential first BLA filing with risto-cel as early as the end of this year, and the pivotal cohort for BEAM-302 is rapidly advancing with completion of dosing expected in the first half of 2027. Recently, initial BEAM-301 clinical trial data showed exciting early evidence of clinical activity and provided further clinical validation of our in vivo LNP platform. Together with the planned initiation of BEAM-304 dosing in early 2027, these milestones reinforce our confidence in a platform designed to translate predictably, carry knowledge forward from one program to the next, and progressively expand the number of patients who can benefit from base editing.”
BEAM-302:BEAM-302, Beam’s lead genetic disease program, is an investigational base editing therapy designed to be a differentiated, first-in-class liver- targeting therapy for alpha-1 antitrypsin deficiency (AATD) that directly corrects the root cause of the disease and has the potential to address both liver and lung manifestations.
In September, Beam presented updated clinical data from the Phase 1/2 trial of BEAM-302 at the European Respiratory Society (ERS) Congress 2026, reinforcing its potential as a one-time treatment for both the lung and liver manifestations of AATD. With up to 18 months of follow-up, the data demonstrated durable increases in total and functional AAT, decreased circulating neutrophil elastase activity, and reductions in mutant Z-AAT and toxic circulating Z-polymers following a single dose. Evidence of AAT production under normal physiological control further supports BEAM-302’s potential to restore the body’s natural protective response, with a safety profile consistent with lipid nanoparticle (LNP)-based therapies.
Enrollment and dosing continue in the global pivotal cohort of the ongoing Phase 1/2 trial, which is designed to support a potential accelerated approval path in the United States. The company expects to complete dosing in the pivotal cohort in the first half of 2027.
BEAM-304:BEAM-304 is an investigational base editing program designed to leverage Beam’s proprietary base editing technology and LNP delivery capabilities to directly and durably correct mutations in the phenylalanine hydroxylase (PAH) gene that cause phenylketonuria (PKU). Beam aims to advance BEAM-304 using a platform approach to develop mutation-specific base editors for the majority of patients with PKU.
Beam nominated its third base editor within the BEAM-304 program targeting a third undisclosed PKU mutation. Now encompassing three different base editors for distinct mutations, the company believes the BEAM-304 program has the potential to address up to 50% of PKU patients in the U.S., with ongoing research effort to address additional pathogenic mutations.
Beam continues clinical start-up activities for the planned Phase 1/2 trial of BEAM-304. The trial will initially evaluate safety, tolerability and reduction of blood phenylalanine (Phe) levels in patients with the R408W mutation, with the goal of establishing clinical proof of concept for base editing in PKU. The trial is designed to subsequently evaluate base editors for additional mutations within a single clinical program. Beam expects to initiate dosing in the Phase 1/2 trial in early 2027.
BEAM-301:BEAM-301, an investigational base editing therapy, aims to correct one of the most common disease-causing mutations, R83C, in patients with glycogen storage disease type Ia (GSDIa).
In October, Beam presented initial clinical data from the ongoing Phase 1/2 trial of BEAM-301 at the European Society of Gene & Cell Therapy (ESGCT) Congress. Initial BEAM-301 clinical data demonstrated dose-dependent improvements in time to fasting hypoglycemia (TTH) across all patients, with two of three patients in the 40 mg cohort achieving the protocol-defined maximum controlled fasting duration of ≥15 hours, consistent with restored endogenous glucose production, and complete elimination of starch supplementation. BEAM-301 demonstrated an acceptable safety profile across both doses, consistent with the known risks associated with LNP-based therapies.
Based on the safety and clinical findings observed to date, Beam is enrolling patients in a 60 mg cohort of the ongoing open-label Phase 1/2 dose-exploration study and plans to engage with the U.S. FDA regarding a potential path to approval.
Risto-cel:Ristoglogene autogetemcel (risto-cel, formerly known as BEAM-101) is an investigational autologous cell therapy with a potentially differentiated profile for the treatment of sickle cell disease (SCD).
Beam continues to make significant investments in developing targeted LNPs to deliver gene editing to hematopoietic stem cells (HSCs). Targeted LNPs for HSC delivery have been identified and are in advanced lead optimization.
In September, Beam appointed Eric Foster as chief commercial officer to lead the company’s commercial organization and strategy as its hematology and genetic disease programs advance toward potential launches. Mr. Foster is a seasoned biopharmaceutical executive with more than 25 years of commercial leadership experience, including senior roles at Ardelyx, Horizon Therapeutics, and GSK.
Beam management will participate in fireside chats at the following upcoming investor events:
The live webcasts will be available in the investor section of the company’s website atwww.beamtx.comand will be archived for 60 days following each presentation.
Cash Position: Cash, cash equivalents and marketable securities were $1.0 billion as of September 30, 2026, compared to $1.2 billion as of December 31, 2025.
Research & Development (R&D) Expenses: R&D expenses were $110.1 million for the third quarter of 2026, compared to $109.8 million for the third quarter of 2025.
General & Administrative (G&A) Expenses : G&A expenses were $31.5 million for the third quarter of 2026, compared to $26.7 million for the third quarter of 2025.
Net Income (Loss): Net loss was $134.4 million, or $1.28 per share, for the third quarter of 2026, compared to net loss of $112.6 million, or $1.10 per share, for the third quarter of 2025.
Beam expects that its cash, cash equivalents and marketable securities as of September 30, 2026, together with an additional $200 million expected to be drawn from the company’s facility with Sixth Street, will fund anticipated operating expenses and capital expenditure requirements into mid-2029, assuming satisfaction of the conditions applicable to those additional borrowings. This runway is expected to support the company through the potential launch of risto- cel in SCD, execution of the BEAM-302 pivotal development plan in AATD, and clinical proof of concept for BEAM-304 in PKU.
Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform with integrated gene editing, delivery and internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting- edge science, and a vision of providing lifelong cures to patients suffering from serious diseases.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Investors are cautioned not to place undue reliance on these forward-looking statements, including, but not limited to, statements related to: the therapeutic applications and potential of our technology, including with respect to SCD, AATD, PKU and GSDIa, and our next-generation programs, including our development of targeted LNPs for hematopoietic stem cell delivery; our plans, and anticipated timing, to advance our programs and present data from ongoing clinical trials; the clinical trial designs and expectations for risto-cel, BEAM-103, BEAM-301, BEAM-302 and BEAM-304, including the anticipated timing of clinical trial initiation and expansion; our planned submission of a BLA for risto-cel; our expectations regarding the potential launch of risto-cel; the potential for an accelerated approval path for BEAM-302; our anticipated regulatory interactions and filings; our expectations regarding the funds that will be available to draw under our credit facility with Sixth Street; the sufficiency of our capital resources to fund operating expenses and capital expenditure requirements and the period in which such resources are expected to be available; our intentions regarding management’s participation in future investor events; and our ability to develop lifelong, curative, precision genetic medicines for patients through base editing. Each forward-looking statement is subject to important risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement, including, without limitation, risks and uncertainties related to: our ability to develop, obtain regulatory approval for, and commercialize our product candidates, which may take longer or cost more than planned; our ability to raise additional funding, which may not be available; our ability to obtain, maintain and enforce patent and other intellectual property protection for our product candidates; the uncertainty that our product candidates will receive regulatory approval necessary to initiate or continue human clinical trials; that preclinical testing of our product candidates and preliminary or interim data from preclinical studies and clinical trials may not be predictive of the results or success of ongoing or later clinical trials; that initiation and enrollment of, and anticipated timing to advance, our clinical trials may take longer than expected; that our product candidates, including the delivery modalities we rely on to administer them, may cause serious adverse events; that we may not achieve the funding milestones under our credit facility with Sixth Street; that our product candidates may experience manufacturing or supply interruptions or failures; risks related to competitive products; and the other risks and uncertainties identified under the headings “Risk Factors Summary” and “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, and in any subsequent filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law.
Full text with the tables
Exhibit 99.1
Beam Therapeutics Reports Third Quarter 2026 Financial Results and Highlights
Clinical Progress Across Base Editing Portfolio
Updated BEAM-302 Phase 1/2 Clinical Data Presented at ERS Demonstrated Durable
Increases in Functional AAT and Reductions in Mutant Z-AAT; Completion of Dosing
in the Global Pivotal Cohort Expected in First Half of 2027
U.S. Biologics License Application (BLA) Submission for Risto-cel in Sickle Cell
Disease Expected as Early as Year-End 2026
Dosing in Phase 1/2 Trial of BEAM-304 in PKU Anticipated to Initiate in Early
2027
Initial BEAM-301 Phase 1/2 Data Presented at ESGCT Demonstrated Clinical Proof
of Concept for Genetic Correction of R83C Mutation in GSDIa; Enrollment in 60 mg
Cohort Underway
Ended Third Quarter 2026 with $1.0 Billion in Cash, Cash Equivalents and
Marketable Securities; Cash Runway Expected to Support Operating Plans into
Mid-2029
Cambridge, Mass., November 3, 2026– Beam Therapeutics Inc. (Nasdaq: BEAM), a
biotechnology company developing precision genetic medicines through base
editing, today reported third quarter 2026 financial results and provided
updates across the company’s hematology and genetic disease franchises.
“Our progress this quarter reflects the growing maturity and momentum of Beam’s
platform, with predictable clinical translation across four distinct programs
and multiple potentially transformative medicines advancing toward patients,
bringing our vision for a new era of genetic medicine increasingly within
reach,” said John Evans, chief executive officer of Beam Therapeutics. “We are
approaching a potential first BLA filing with risto-cel as early as the end of
this year, and the pivotal cohort for BEAM-302 is rapidly advancing with
completion of dosing expected in the first half of 2027. Recently, initial
BEAM-301 clinical trial data showed exciting early evidence of clinical activity
and provided further clinical validation of our in vivo LNP platform. Together
with the planned initiation of BEAM-304 dosing in early 2027, these milestones
reinforce our confidence in a platform designed to translate predictably, carry
knowledge forward from one program to the next, and progressively expand the
number of patients who can benefit from base editing.”
Third Quarter 2026 and Recent Progress and Anticipated Milestones
Liver-targeted Genetic Diseases
BEAM-302:BEAM-302, Beam’s lead genetic disease program, is an investigational
base editing therapy designed to be a differentiated, first-in-class liver-
targeting therapy for alpha-1 antitrypsin deficiency (AATD) that directly
corrects the root cause of the disease and has the potential to address both
liver and lung manifestations.
In September, Beam presented updated clinical data from the Phase 1/2 trial of
BEAM-302 at the European Respiratory Society (ERS) Congress 2026, reinforcing
its potential as a one-time treatment for both the lung and liver manifestations
of AATD. With up to 18 months of follow-up, the data demonstrated durable
increases in total and functional AAT, decreased circulating neutrophil elastase
activity, and reductions in mutant Z-AAT and toxic circulating Z-polymers
following a single dose. Evidence of AAT production under normal physiological
control further supports BEAM-302’s potential to restore the body’s natural
protective response, with a safety profile consistent with lipid nanoparticle
(LNP)-based therapies.
Enrollment and dosing continue in the global pivotal cohort of the ongoing Phase
1/2 trial, which is designed to support a potential accelerated approval path in
the United States. The company expects to complete dosing in the pivotal cohort
in the first half of 2027.
BEAM-304:BEAM-304 is an investigational base editing program designed to
leverage Beam’s proprietary base editing technology and LNP delivery
capabilities to directly and durably correct mutations in the phenylalanine
hydroxylase (PAH) gene that cause phenylketonuria (PKU). Beam aims to advance
BEAM-304 using a platform approach to develop mutation-specific base editors for
the majority of patients with PKU.
Beam nominated its third base editor within the BEAM-304 program targeting a
third undisclosed PKU mutation. Now encompassing three different base editors
for distinct mutations, the company believes the BEAM-304 program has the
potential to address up to 50% of PKU patients in the U.S., with ongoing
research effort to address additional pathogenic mutations.
Beam continues clinical start-up activities for the planned Phase 1/2 trial of
BEAM-304. The trial will initially evaluate safety, tolerability and reduction
of blood phenylalanine (Phe) levels in patients with the R408W mutation, with
the goal of establishing clinical proof of concept for base editing in PKU. The
trial is designed to subsequently evaluate base editors for additional mutations
within a single clinical program. Beam expects to initiate dosing in the Phase
1/2 trial in early 2027.
BEAM-301:BEAM-301, an investigational base editing therapy, aims to correct one
of the most common disease-causing mutations, R83C, in patients with glycogen
storage disease type Ia (GSDIa).
In October, Beam presented initial clinical data from the ongoing Phase 1/2
trial of BEAM-301 at the European Society of Gene & Cell Therapy (ESGCT)
Congress. Initial BEAM-301 clinical data demonstrated dose-dependent
improvements in time to fasting hypoglycemia (TTH) across all patients, with two
of three patients in the 40 mg cohort achieving the protocol-defined maximum
controlled fasting duration of ≥15 hours, consistent with restored endogenous
glucose production, and complete elimination of starch supplementation. BEAM-301
demonstrated an acceptable safety profile across both doses, consistent with the
known risks associated with LNP-based therapies.
Based on the safety and clinical findings observed to date, Beam is enrolling
patients in a 60 mg cohort of the ongoing open-label Phase 1/2 dose-exploration
study and plans to engage with the U.S. FDA regarding a potential path to
approval.
Hematology
Risto-cel:Ristoglogene autogetemcel (risto-cel, formerly known as BEAM-101) is
an investigational autologous cell therapy with a potentially differentiated
profile for the treatment of sickle cell disease (SCD).
Beam expects to report updated clinical data by year-end 2026 and submit a U.S.
biologics license application (BLA) for risto-cel as early as year-end 2026.
Next-generation Programs in Sickle Cell Disease and Hematology:
Beam continues to make significant investments in developing targeted LNPs to
deliver gene editing to hematopoietic stem cells (HSCs). Targeted LNPs for HSC
delivery have been identified and are in advanced lead optimization.
Corporate Updates
In September, Beam appointed Eric Foster as chief commercial officer to lead the
company’s commercial organization and strategy as its hematology and genetic
disease programs advance toward potential launches. Mr. Foster is a seasoned
biopharmaceutical executive with more than 25 years of commercial leadership
experience, including senior roles at Ardelyx, Horizon Therapeutics, and GSK.
Upcoming Events
Beam management will participate in fireside chats at the following upcoming
investor events:
Guggenheim 3 rd Annual Healthcare Innovation Conference in Boston:
Tuesday, November 10, 2026, at 9:00 a.m. ET.
UBS Global Biopharma Conference in London:
Tuesday, November 17, 2026, at 2:00 p.m. GMT.
Jefferies Global Healthcare Conference in London:
Wednesday, November 18, 2026, at 1:00 p.m. GMT.
9 th Annual Evercore Healthcare Conference in Miami:
Wednesday, December 2, 2026, at 8:20 a.m. ET.
The live webcasts will be available in the investor section of the company’s
website atwww.beamtx.comand will be archived for 60 days following each
presentation.
Third Quarter 2026 Financial Results
Cash Position: Cash, cash equivalents and marketable securities were $1.0
billion as of September 30, 2026, compared to $1.2 billion as of December 31,
2025.
Research & Development (R&D) Expenses: R&D expenses were $110.1 million for the
third quarter of 2026, compared to $109.8 million for the third quarter of 2025.
General & Administrative (G&A) Expenses : G&A expenses were $31.5 million for
the third quarter of 2026, compared to $26.7 million for the third quarter of
2025.
Net Income (Loss): Net loss was $134.4 million, or $1.28 per share, for the
third quarter of 2026, compared to net loss of $112.6 million, or $1.10 per
share, for the third quarter of 2025.
Cash Runway
Beam expects that its cash, cash equivalents and marketable securities as of
September 30, 2026, together with an additional $200 million expected to be
drawn from the company’s facility with Sixth Street, will fund anticipated
operating expenses and capital expenditure requirements into mid-2029, assuming
satisfaction of the conditions applicable to those additional borrowings. This
runway is expected to support the company through the potential launch of risto-
cel in SCD, execution of the BEAM-302 pivotal development plan in AATD, and
clinical proof of concept for BEAM-304 in PKU.
About Beam Therapeutics
Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to
establishing the leading, fully integrated platform for precision genetic
medicines. To achieve this vision, Beam has assembled a platform with integrated
gene editing, delivery and internal manufacturing capabilities. Beam’s suite of
gene editing technologies is anchored by base editing, a proprietary technology
that is designed to enable precise, predictable and efficient single base
changes, at targeted genomic sequences, without making double-stranded breaks in
the DNA. This has the potential to enable a wide range of therapeutic editing
strategies that Beam is using to advance a diversified portfolio of base editing
programs. Beam is a values-driven organization committed to its people, cutting-
edge science, and a vision of providing lifelong cures to patients suffering
from serious diseases.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Investors are cautioned not to
place undue reliance on these forward-looking statements, including, but not
limited to, statements related to: the therapeutic applications and potential of
our technology, including with respect to SCD, AATD, PKU and GSDIa, and our
next-generation programs, including our development of targeted LNPs for
hematopoietic stem cell delivery; our plans, and anticipated timing, to advance
our programs and present data from ongoing clinical trials; the clinical trial
designs and expectations for risto-cel, BEAM-103, BEAM-301, BEAM-302 and
BEAM-304, including the anticipated timing of clinical trial initiation and
expansion; our planned submission of a BLA for risto-cel; our expectations
regarding the potential launch of risto-cel; the potential for an accelerated
approval path for BEAM-302; our anticipated regulatory interactions and filings;
our expectations regarding the funds that will be available to draw under our
credit facility with Sixth Street; the sufficiency of our capital resources to
fund operating expenses and capital expenditure requirements and the period in
which such resources are expected to be available; our intentions regarding
management’s participation in future investor events; and our ability to develop
lifelong, curative, precision genetic medicines for patients through base
editing. Each forward-looking statement is subject to important risks and
uncertainties that could cause actual results to differ materially from those
expressed or implied in such statement, including, without limitation, risks and
uncertainties related to: our ability to develop, obtain regulatory approval
for, and commercialize our product candidates, which may take longer or cost
more than planned; our ability to raise additional funding, which may not be
available; our ability to obtain, maintain and enforce patent and other
intellectual property protection for our product candidates; the uncertainty
that our product candidates will receive regulatory approval necessary to
initiate or continue human clinical trials; that preclinical testing of our
product candidates and preliminary or interim data from preclinical studies and
clinical trials may not be predictive of the results or success of ongoing or
later clinical trials; that initiation and enrollment of, and anticipated timing
to advance, our clinical trials may take longer than expected; that our product
candidates, including the delivery modalities we rely on to administer them, may
cause serious adverse events; that we may not achieve the funding milestones
under our credit facility with Sixth Street; that our product candidates may
experience manufacturing or supply interruptions or failures; risks related to
competitive products; and the other risks and uncertainties identified under the
headings “Risk Factors Summary” and “Risk Factors” in our Annual Report on Form
10-K for the year ended December 31, 2025, and in any subsequent filings with
the Securities and Exchange Commission. These forward-looking statements speak
only as of the date of this press release. Factors or events that could cause
our actual results to differ may emerge from time to time, and it is not
possible for us to predict all of them. We undertake no obligation to update any
forward-looking statement, whether as a result of new information, future
developments or otherwise, except as may be required by applicable law.
Contacts:
Investors:
Holly Manning
Beam Therapeutics
[email protected]
Media:
Josie Butler
1AB
[email protected]
Condensed Consolidated Balance Sheet
Data (unaudited) September 30, December 31,
(in thousands) 2026 2025
──────────────────────────────────────────────────────────────────────────────
Cash, cash equivalents, and
marketable $ 1,043,873 $ 1,245,210
securities
Total assets 1,269,072 1,481,177
Total liabilities 316,398 242,819
Total stockholders’ equity 952,674 1,238,358
Con…
Con…
Sta…
of
Ope…
(un…
(in
tho…
exc…
sha…
and
per
sha…
dat…
Three Nine
Mont… Mont…
Ended Ended
Sept… Sept…
30, 30,
2026 2025 2026 2025
Lic…
and $ 307 $ 9,6… $ 32,… $ 25,6…
col…
rev…
Ope…
exp…
Res…
and 110,… 109… 309… 310,…
dev…
Gen…
and 31,5… 26,… 97,… 81,5…
adm…
Tot…
ope… 141,… 136… 407… 391,…
exp…
Loss
from (141… ) (12… ) (37… ) (366… )
ope…
Oth…
inc…
(ex…
Cha…
in
fair
val… 4,700 (2,… ) 3,0… 1,900
of
der…
lia…
Cha…
in
fair
val… (1,0… ) 4,9… (667 ) 7,271
of
non…
equ…
inv…
Cha…
in
fair
val… (2,8… ) 1,0… (2,… ) 945
of
con…
con…
lia…
Gain
on
sale
of — — 455 —
equ…
met…
inv…
Int…
and
oth… 6,094 10,… 23,… 33,0…
inc…
(ex…
net
Tot…
oth… 6,917 14,… 23,… 43,2…
inc…
(ex…
Net $ (134… ) $ (11… ) $ (35… ) $ (323… )
loss
Unr…
gain
(lo… (1,2… ) 780 (4,… ) 111
on
mar…
sec…
Com… $ (135… ) $ (11… ) $ (35… ) $ (322… )
loss
Net
loss
per
com… $ (1.28 ) $ (1.… ) $ (3.… ) $ (3.31 )
sha…
bas…
and
dil…
Wei…
com…
sha…
out… 104,… 102… 104… 97,5…
bas…
and
dil…